- Home
- ARQT vs ONDS Comparison
ARQT vs ONDS Comparison
Compare ARQT & ONDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARQT | ONDS |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.6B |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ARQT | ONDS |
|---|---|---|
| Price | $25.67 | $5.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $39.13 | $18.88 |
| AVG Volume (30 Days) | 2.2M | ★ 41.2M |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.79 | N/A |
| EPS | 0.09 | ★ 0.38 |
| Revenue | ★ $376,072,000.00 | $50,731,000.00 |
| Revenue This Year | $43.21 | $957.99 |
| Revenue Next Year | $29.18 | $88.66 |
| P/E Ratio | $346.22 | ★ $13.92 |
| Revenue Growth | 91.34 | ★ 605.31 |
| 52 Week Low | $19.30 | $5.22 |
| 52 Week High | $34.80 | $15.28 |
Technical Indicators
Market Signals| Indicator | ARQT | ONDS |
|---|---|---|
| Relative Strength Index (RSI) | 36.87 | 38.09 |
| Support Level | $23.42 | N/A |
| Resistance Level | $28.54 | $11.77 |
| Average True Range (ATR) | 1.50 | 0.47 |
| MACD | -0.68 | -0.10 |
| Stochastic Oscillator | 4.63 | 35.49 |
Price Performance
Historical ComparisonAbout ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
About ONDS Ondas Holdings Inc.
Ondas Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system. Geographically, the company operates in Israel, Germany, United Arab Emirates, United States, and Other Countries. It derives maximum revenue from Israel.